PAD-Focused Medtechs Eye Golden Period In Growing Silver Market

Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.

Demographic changes are one of the key growth factors driving the market for peripheral vascular interventions and diagnostics for peripheral artery disease (PAD). Other factors include new technological developments, such as drug-eluting balloons, which are improving clinical success rates and expanding the number of patients who can be treated.

The initial approach to assessing a patient with suspected PAD is to measure the ankle brachial pressure index (ABI), which...

More from Archive

More from In Vivo